This DoD grant is designed to support the critical preclinical assessment of therapeutics aimed at combating Amyotrophic Lateral Sclerosis (ALS). The primary objective is to fund empirical and product-driven studies focused on developing new treatments for this devastating neurodegenerative disease. While researchers may adopt a hypothesis-driven approach, the core emphasis must remain firmly on therapeutic development. Successful projects under this award are expected to generate valuable data and promising therapeutic agents. The ultimate goal is to accelerate the advancement of innovative new therapies for ALS patients, bridging the gap from discovery to potential clinical application. This grant plays a vital role in fostering advancements crucial for addressing the unmet medical needs of the ALS community.
Opportunity ID: 150953
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-12-ALSRP-TDA |
| Funding Opportunity Title: | DoD Amyotrophic Lateral Sclerosis Therapeutic Development Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 08, 2012 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Jul 24, 2012 |
| Current Closing Date for Applications: | Jul 24, 2012 |
| Archive Date: | Aug 23, 2012 |
| Estimated Total Program Funding: | $4,800,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The Therapeutic Development Award supports the preclinical assessment of therapeutics for ALS. The proposed studies are expected to be empirical in nature and product-driven but may have a hypothesis-driven approach, provided the focus is on therapeutics. It is anticipated that the agents and/or data generated from these awards will lead to the advancement of new therapies for ALS. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
301-682-5507; help@cdmrp.org
Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 150953 Full Announcement-1 -> fy12 alsrp tda pa_gg.pdf
Folder 150953 Revised Full Announcement-1 -> w81xwh-12-alsrp-tda ver 2.pdf
Packages
| Agency Contact Information: | 301-682-5507; help@cdmrp.org Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00103670 | Mar 08, 2012 | Jul 24, 2012 | View |
Package 1
Mandatory forms
150953 RR_SF424_1_2-1.2.pdf
150953 PerformanceSite_1_4-1.4.pdf
150953 RR_Budget-1.1.pdf
150953 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
150953 RR_SubawardBudget30-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
